Market Cap (In SEK)
2.38 Billion
Revenue (In SEK)
57.6 Million
Net Income (In SEK)
-326.9 Million
Avg. Volume
412.79 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 4.04-9.3
- PE
- -
- EPS
- -
- Beta Value
- 1.43
- ISIN
- SE0003815604
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Nicklas Westerholm
- Employee Count
- -
- Website
- https://www.egetis.com
- Ipo Date
- 2011-04-07
- Details
- Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
More Stocks
-
WAYS
-
INFIBEAMInfibeam Avenues Limited
INFIBEAM
-
DRILDrillcon AB (publ)
DRIL
-
GANECOSGanesha Ecosphere Limited
GANECOS
-
PLAZ-B
-
RTNPOWERRattanIndia Power Limited
RTNPOWER
-
BRI
-
ALDE